Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - CAPSULE;ORAL - EQ 100MG BASE
USFDA APPLICATION NUMBER - 21411
DOSAGE - CAPSULE;ORAL - EQ 10MG BASE
USFDA APPLICATION NUMBER - 21411
DOSAGE - CAPSULE;ORAL - EQ 18MG BASE
USFDA APPLICATION NUMBER - 21411
DOSAGE - CAPSULE;ORAL - EQ 25MG BASE
USFDA APPLICATION NUMBER - 21411
DOSAGE - CAPSULE;ORAL - EQ 40MG BASE
USFDA APPLICATION NUMBER - 21411
DOSAGE - CAPSULE;ORAL - EQ 60MG BASE
USFDA APPLICATION NUMBER - 21411
DOSAGE - CAPSULE;ORAL - EQ 80MG BASE
USFDA APPLICATION NUMBER - 21411
Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Fillers, Diluents & Binders
Coating Systems & Additives
Thickeners and Stabilizers
Empty Capsules
Direct Compression
Taste Masking
Lubricants & Glidants
Film Formers & Plasticizers
Granulation
Topical
Co-Processed Excipients
Disintegrants & Superdisintegrants
Coloring Agents
Emulsifying Agents
Chewable & Orodispersible Aids
Solubilizers
Controlled & Modified Release
Parenteral
API Stability Enhancers
Surfactant & Foaming Agents
Rheology Modifiers
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
78
PharmaCompass offers a list of Atomoxetin Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Atomoxetin Hydrochloride manufacturer or Atomoxetin Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Atomoxetin Hydrochloride manufacturer or Atomoxetin Hydrochloride supplier.
PharmaCompass also assists you with knowing the Atomoxetin Hydrochloride API Price utilized in the formulation of products. Atomoxetin Hydrochloride API Price is not always fixed or binding as the Atomoxetin Hydrochloride Price is obtained through a variety of data sources. The Atomoxetin Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Atomoxetine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Atomoxetine, including repackagers and relabelers. The FDA regulates Atomoxetine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Atomoxetine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Atomoxetine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Atomoxetine supplier is an individual or a company that provides Atomoxetine active pharmaceutical ingredient (API) or Atomoxetine finished formulations upon request. The Atomoxetine suppliers may include Atomoxetine API manufacturers, exporters, distributors and traders.
click here to find a list of Atomoxetine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Atomoxetine DMF (Drug Master File) is a document detailing the whole manufacturing process of Atomoxetine active pharmaceutical ingredient (API) in detail. Different forms of Atomoxetine DMFs exist exist since differing nations have different regulations, such as Atomoxetine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Atomoxetine DMF submitted to regulatory agencies in the US is known as a USDMF. Atomoxetine USDMF includes data on Atomoxetine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Atomoxetine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Atomoxetine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Atomoxetine Drug Master File in Japan (Atomoxetine JDMF) empowers Atomoxetine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Atomoxetine JDMF during the approval evaluation for pharmaceutical products. At the time of Atomoxetine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Atomoxetine suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Atomoxetine Drug Master File in Korea (Atomoxetine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Atomoxetine. The MFDS reviews the Atomoxetine KDMF as part of the drug registration process and uses the information provided in the Atomoxetine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Atomoxetine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Atomoxetine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Atomoxetine suppliers with KDMF on PharmaCompass.
A Atomoxetine CEP of the European Pharmacopoeia monograph is often referred to as a Atomoxetine Certificate of Suitability (COS). The purpose of a Atomoxetine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Atomoxetine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Atomoxetine to their clients by showing that a Atomoxetine CEP has been issued for it. The manufacturer submits a Atomoxetine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Atomoxetine CEP holder for the record. Additionally, the data presented in the Atomoxetine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Atomoxetine DMF.
A Atomoxetine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Atomoxetine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Atomoxetine suppliers with CEP (COS) on PharmaCompass.
A Atomoxetine written confirmation (Atomoxetine WC) is an official document issued by a regulatory agency to a Atomoxetine manufacturer, verifying that the manufacturing facility of a Atomoxetine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Atomoxetine APIs or Atomoxetine finished pharmaceutical products to another nation, regulatory agencies frequently require a Atomoxetine WC (written confirmation) as part of the regulatory process.
click here to find a list of Atomoxetine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Atomoxetine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Atomoxetine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Atomoxetine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Atomoxetine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Atomoxetine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Atomoxetine suppliers with NDC on PharmaCompass.
Atomoxetine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Atomoxetine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Atomoxetine GMP manufacturer or Atomoxetine GMP API supplier for your needs.
A Atomoxetine CoA (Certificate of Analysis) is a formal document that attests to Atomoxetine's compliance with Atomoxetine specifications and serves as a tool for batch-level quality control.
Atomoxetine CoA mostly includes findings from lab analyses of a specific batch. For each Atomoxetine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Atomoxetine may be tested according to a variety of international standards, such as European Pharmacopoeia (Atomoxetine EP), Atomoxetine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Atomoxetine USP).
